Rafael Holdings Files Amendment to 8-K
Ticker: RFL · Form: 8-K/A · Filed: May 23, 2024 · CIK: 1713863
Sentiment: neutral
Topics: amendment, 8-K, filing-correction
TL;DR
Rafael Holdings amended its 8-K filing from March 13, 2024, with no new material info, just a correction.
AI Summary
Rafael Holdings, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on May 23, 2024, related to financial statements and exhibits. The original report date was March 13, 2024. The filing does not appear to contain new material financial information but rather an amendment to a previous filing.
Why It Matters
This amendment clarifies or corrects previously filed information, ensuring the accuracy of public disclosures for investors and regulatory bodies.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, likely for administrative or minor correction purposes, and does not introduce new risks.
Key Players & Entities
- Rafael Holdings, Inc. (company) — Registrant
- March 13, 2024 (date) — Original report date
- May 23, 2024 (date) — Filing date of amendment
- 520 Broad Street, Newark, New Jersey 07102 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K/A filing?
This filing is Amendment No. 1 to a Form 8-K, intended to amend or supplement information previously reported.
What was the original report date for the Form 8-K being amended?
The earliest event reported in the original Form 8-K was March 13, 2024.
When was this amendment filed with the SEC?
This amendment was filed as of date May 23, 2024.
What is the principal executive office address for Rafael Holdings, Inc.?
The address is 520 Broad Street, Newark, New Jersey 07102.
What is the SIC code for Rafael Holdings, Inc.?
The Standard Industrial Classification (SIC) code is 6500, categorized under Real Estate.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 9.6 · Accepted 2024-05-23 08:15:59
Key Financial Figures
- $0.01 — tered Class B common stock, par value $0.01 per share RFL New York Stock Exchan
Filing Documents
- ea0206676-8ka1_rafael.htm (8-K/A) — 32KB
- ea020667601ex23-1_rafael.htm (EX-23.1) — 3KB
- ea020667601ex99-1_rafael.htm (EX-99.1) — 335KB
- ea020667601ex99-2_rafael.htm (EX-99.2) — 318KB
- ea020667601ex99-3_rafael.htm (EX-99.3) — 389KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_002.jpg (GRAPHIC) — 16KB
- ex99-1_003.jpg (GRAPHIC) — 4KB
- 0001213900-24-046085.txt ( ) — 1423KB
- rfl-20240313.xsd (EX-101.SCH) — 3KB
- rfl-20240313_lab.xml (EX-101.LAB) — 33KB
- rfl-20240313_pre.xml (EX-101.PRE) — 22KB
- ea0206676-8ka1_rafael_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired. The audited financial statements of Cornerstone Pharmaceuticals, Inc. ("Cornerstone") as of and for the year ended July 31, 2023 and the unaudited financial statements of Cornerstone as of and for the three months ended October 31, 2023. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined financial information of the Company giving effect to the various transactions which effected a recapitalization and restructuring of Cornerstone, the acquisition by the Company of a controlling interest in Cornerstone, and the consolidation of RP Finance LLC, are filed herewith as Exhibit 99.2. (d) Exhibits. Exhibit No. Document 23.1 Consent of CohnReznick LLP 99.1 Audited Financial statements of Cornerstone Pharmaceuticals, Inc. as of and for the year ended July 31, 2023. 99.2 Unaudited Financial statements of Cornerstone Pharmaceuticals, Inc. as of and for the three months ended October 31, 2023 99.3 The unaudited proforma condensed combined financial statements of the Company. 104 Cover Page Interactive Data File, formatted in Inline XBRL document. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAFAEL HOLDINGS, INC. By: /s/ William Conkling Name: William Conkling Title: Chief Executive Officer Dated: May 23, 2024 2 EXHIBIT INDEX Exhibit No. Document 23.1 Consent of CohnReznick LLP 99.1 Audited Financial statements of Cornerstone Pharmaceuticals, Inc. as of and for the year ended July 31, 2023. 99.2 Unaudited Financial statements of Cornerstone Pharmaceuticals, Inc. as of and for the three months ended October 31, 2023 99.3 The unaudited proforma condensed combined financial statements of the Company. 104 Cover Page Interactive Data File, formatted in Inline XBRL document. 3